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Abstract 
Objective: Magnetic seizure therapy (MST) is under development as an alternative to 
electroconvulsive therapy (ECT), as it offers reduction in depression symptoms with fewer 
adverse cognitive effects. This study examined the feasibility and efficacy of MST versus ECT 
in a randomized trial of geriatric patients with severe depression, then compared the 
neurophysiological characteristics of seizures induced by MST or ECT and investigated potential 
links between seizure expression and therapeutic response.  
Method: Six patients (mean age: 64.8) with severe depression were randomized to receive MST 
(n=3) or ECT (n=3) until maximal antidepressant effect (mean number of sessions: 14.67). 
Depression symptoms were assessed pre- and post-treatment using the Hamilton Rating Scale for 
Depression. Neuropsychological tests of verbal ability, visuospatial ability, memory, fluency, 
executive functioning, and motor functioning were administered pre- and post-treatment. 64-
channel electroencephalogram (EEG) recordings were obtained at the start and end of treatment 
to capture power during ictal (seizure) and post-ictal periods for delta, theta, alpha, beta, and 
gamma frequency bands.  
Results: Two ECT and three MST patients achieved remission of depression symptoms. EEG 
power and test performance did not differ between treatments. Ictal power and post-ictal 
suppression increased from the start to end of treatment in all frequency bands for the responders 
but not the non-responder. Increases in gamma ictal power and post-ictal suppression predicted 
slowing on a task of visuomotor skill and executive functioning, while increases in beta and theta 
ictal power and post-ictal suppression predicted improvement on a task of verbal fluency.  
Conclusions: MST continues to show promise as an efficacious and feasible alternative to ECT. 
For both MST and ECT, increases in ictal power and post-ictal suppression in all frequency 
bands may be indicators of treatment response, and associated with impairments to visuomotor 
functioning.  
Keywords: Electroconvulsive therapy, magnetic seizure therapy, EEG, ictal power, post-ictal 
suppression 
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Introduction 
Electroconvulsive therapy (ECT) has long been established as an efficacious treatment for severe 
depression (Engel & Kayser, 2016; Kho, van Vreeswijk, Simpson, & Zwinderman, 2003). With 
a 60% remission rate in adults with depression and about a 50% response rate for treatment-
resistant depression, ECT is at least as equally effective as antidepressant medications, especially 
for individuals who have undergone multiple medication trials without success (Blumberger, 
Hsu, & Daskalakis, 2015). Geriatric patients are preferentially referred for ECT over younger 
patients, perhaps due to intolerance to antidepressants, histories of treatment non-response, and 
greater probability of having cardiovascular diseases (Dombrovski & Mulsant, 2007). Not only is 
ECT considered safer than medication in regards to cardiovascular risk, but there is evidence that 
ECT is more effective than pharmacotherapy alone in depressed geriatric patients (Philibert, 
Lynch, & Winokur, 1995).  
 
During ECT, small electric currents are passed through the skull and into the brain of the 
anesthetized patient in order to trigger a brief seizure. Despite strong support for its efficacy, a 
major concern regarding ECT is its adverse cognitive effects, which impact more than 40% of 
patients (Engel et al., 2016). These adverse effects include disorientation lasting up to 40 
minutes, retrograde and anterograde amnesia, difficulty concentrating, and slowed processing 
(Dybedal, Tanum, Sundet, Gaarden, & Bjølseth, 2014). The severity of these cognitive effects 
has been associated with advancing age, which is especially relevant to the depressed geriatric 
population (Sackeim et al., 2007). There is ongoing debate regarding the chronicity of ECT’s 
adverse effects, where one systematic review reported no long-term adverse cognitive effects 
lasting more than six months following treatment (Kumar et al., 2016), while another study 
reported slowed reaction time and impaired memory at six month follow-up (Sackeim et al., 
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2007). Nevertheless, anecdotal evidence of permanent memory loss raises concerns among 
potential patients.  
 
Magnetic seizure therapy (MST) is under development as an alternative to conventional ECT in 
the treatment of severe depression. MST uses high frequency repetitive transcranial magnetic 
stimulation (rTMS) to induce seizures. A coil placed near the patient’s head generates a magnetic 
field that can pass through the scalp and skull to induce a small electric current in the brain. In 
2008, rTMS at low frequencies was approved in the U.S. as treatment for depression in 
medication non-responders up to 69 years old (NIMH, 2016). rTMS reduces depressive 
symptoms with only transient discomfort during stimulation and no cognitive effects 
(Blumberger et al., 2015; Loo & Mitchell, 2005). However, its efficacy is lower than that of ECT 
(George et al., 2010), and there is little evidence of its efficacy specifically in geriatric 
populations. By using higher frequencies of stimulation (> 50 Hz), MST may amplify the 
antidepressant effect of rTMS by inducing a seizure similarly to ECT. The development of MST 
aims to combine the lower side effect profile of rTMS with the efficacy found from seizure 
induction in ECT.  
 
In developing and testing MST, both its efficacy and adverse effects must be considered and 
balanced to determine its feasibility as an alternative treatment. In ECT, efficacy and side effects 
are both influenced by the site of seizure induction and the extent of stimulation (Sackeim et al., 
2008), which are difficult to control using conventional ECT protocol. There is ongoing debate 
regarding the parameters of ECT administration that would best maintain efficacy while 
minimizing side effects, such as number and location of stimulation sites, and the importance of 
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individual seizure thresholds (Abrams, 2002). However, since the skull has a high impedance, it 
shunts electrical current through the scalp and cerebrospinal fluid surrounding the brain, 
resulting in widespread stimulation of cortical and subcortical regions regardless of ECT 
configuration (Cretaz, Brunoni, & Lafer, 2015). A simulation study showed that standard ECT 
configurations can stimulate up to 94% of brain volume at a suprathreshold level, with the 
hippocampus being exposed to stimulation in all ECT configurations (Lee, Lisanby, Laine, & 
Peterchev, 2016). Subcortical and hippocampal activation during ECT is thought to contribute to 
its cognitive side effects.  
 
By contrast, MST uses magnetic stimulation that bypasses the skull, which avoids the issue of 
skull impedance and shunting, thus offering better control over the spatial distribution of 
stimulation (Cretaz et al., 2015). Both simulations and intracerebral recordings have shown that 
MST induces less intense electric fields that are more confined to superficial cortex (Hoy & 
Fitzgerald, 2011; Lee et al., 2016; Lisanby, Luber, Schlaepfer, & Sackeim, 2003). With more 
confined stimulation, MST offers reduced risk of hippocampal activation, which may result in 
fewer memory-related side effects.  
 
The first MST device was a custom rTMS machine and was tested in preclinical trials in 2000, 
followed by the first human test in 2001, which resulted in a reduction in depression score 
(Lisanby, Schlaepfer, Fisch, & Sackeim, 2001). Since then, several open-label studies have 
demonstrated the efficacy of MST and that its antidepressant response was comparable to that of 
ECT (Kayser et al., 2011, 2015; Kosel, Frick, Lisanby, Fisch, & Schlaepfer, 2003). In addition, 
MST resulted in fewer cognitive side effects and faster reorientation than ECT (Cycowicz, 
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Luber, Spellman, & Lisanby, 2009; Kayser, Bewernick, Hurlemann, Soehle, & Schlaepfer, 2013; 
Lisanby et al., 2003; Moscrip, Terrace, Sackeim, & Lisanby, 2006). Therefore, MST shows 
promise as an efficacious alternative to ECT. However, the mechanism by which they elicit 
therapeutic response is still unclear, though there are several hypotheses, including localized 
suppression of neural metabolic activity, adaptive changes in monoamine neurotransmitter 
systems, regulation of the hypothalamic-pituitary-adrenal axis, and influences on neural 
plasticity and neurogenesis (Charney, Menkes, & Heninger, 1981; Merkl, Heuser, & Bajbouj, 
2009; Sackeim, Decina, Prohovnik, Malitz, & Resor, 1983).  
 
Examining characteristics of the seizures induced by ECT and MST may improve understanding 
of their therapeutic mechanisms by pinpointing properties correlated with antidepressant 
response. Electroencephalography (EEG) can be used to measure electrical brain activity at the 
scalp level before, during (ictal), and after (post-ictal) seizures. Studies of simultaneous EEG-
ECT have shown that greater total ictal power, delta power, and post-ictal suppression, the 
difference between ictal and post-ictal power, are predictive of better response to treatment 
(Luber et al., 2000; Mayur, 2006; Nobler et al., 2000; Perera et al., 2004). When comparing the 
neurophysiological characteristics of MST and ECT using two-channel EEG in non-human 
primates, ECT resulted in significantly greater ictal power and post-ictal suppression for all 
frequency bands compared to MST (Cycowicz et al., 2009; Lisanby et al., 2003). However, these 
differences may have been due to limitations of the MST and recording equipment, and it is 
unknown whether the association between ictal power, post-ictal suppression, and therapeutic 
response adheres for MST in humans as well. It may not be necessary to induce as intense of an 
electric field or seizure using MST in order to elicit therapeutic effects. In fact, a reduced electric 
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field may be advantageous in that the current and the seizure would stay confined to superficial 
cortex, reducing the likelihood of generalization to limbic structures involved with memory. 
Further exploration of the differences in ictal and post-ictal expression between MST and ECT 
and their relation to treatment response may clarify mechanisms of therapeutic action in induced 
seizures, and identify seizure parameters to be optimized for efficacy.   
 
Though general neurophysiological characteristics of ECT have been identified, EEG research in 
brain stimulation therapies has thus far been limited by technological challenges. Most EEG 
studies (Lisanby et al., 2003; Cycowicz et al., 2009) have used passive electrodes, which have no 
built-in circuitry and are therefore better able to withstand currents applied from ECT or MST. 
However, it is difficult to detect smaller signals with passive electrodes than with active 
electrodes, which have built-in circuitry to amplify the signal even before it reaches the 
amplifier, thereby improving signal quality dramatically. The downside of active electrodes used 
to be their dysfunction when subjected to high input from ECT, MST, or TMS, but that has been 
resolved in recent iterations of more durable active electrode caps. Unlike past comparisons of 
MST and ECT that used two-channel passive caps, the current study uses a 64-channel active 
cap. Recording with a high-density active cap not only results in better signal quality, 
particularly for low-amplitude high-frequency oscillations, but it can also show differential ictal 
expression from different brain regions.  
 
The current study of MST and ECT has two major goals: First is to evaluate the feasibility and 
antidepressant efficacy of MST in elderly patients with severe depression. We hypothesize that 
MST will result in a significant decrease in depressive symptoms. Demonstrating the usability of 
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MST would further its development as a safer and more favorable alternative treatment to 
conventional ECT. The second goal of the current study is to compare the neurophysiological 
characteristics of MST and ECT in human patients. In line with findings in non-human primates, 
we expect that MST will show lower ictal power and therefore less post-ictal suppression. To 
date, this is the first simultaneous high-density EEG-MST study in humans using an active cap.  
Investigating both treatments through high-density EEG may provide insight into the 
mechanisms by which elicited seizures result in differing therapeutic response in depressed 
patients.  
 
Methods 
This study was approved by the New York State Psychiatric Institute (NYSPI) Institutional 
Review Board.  
 
Participants 
Fifteen eligible individuals enrolled in the study and began treatment. Two participants withdrew 
from the study prior to completion. Complete sets of EEG recordings were obtained for eight 
participants. Two participants’ data were omitted from analyses due to issues with recording. Of 
the remaining six participants, five were female. The six participants ranged in age from 57 to 74 
years old (mean: 64.8, standard deviation [SD]: 7.41, Table 1).  
 
All participants were between the ages of 55 and 90 and willing and capable of providing 
informed consent. Participants were recruited via flyers and brochures at NYSPI, as well as 
referral by private physicians and clinical services at NYSPI and other psychiatric facilities. 
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Participants were eligible to participate if they had received a clinical diagnosis of a major 
depressive episode in the context of unipolar or bipolar disorder, a Hamilton Rating Scale for 
Depression (HRSD) score ≥ 20 (indicating severe symptoms of depression), and a Mini Mental 
State Exam score ≥ 24 (indicating normal cognition). Outpatients enrolling in the study needed 
to be living with a responsible adult to provide support and oversee treatment adherence. 
Participants were excluded if they had a history of schizophrenia, schizoaffective disorder, rapid 
cycling bipolar disorder, or substance abuse or dependence within the last three months as 
determined by the Structured Clinical Interview for Diagnosis (SCID-IV) and a urine toxicology 
screen. Participants were also excluded if they had a current unstable or serious medical 
condition, or any medical condition that substantially increased the risks associated with MST or 
ECT as determined by physician evaluation. Participants with a history of neurological disorder, 
epilepsy, stroke, brain surgery, metal in the head, known brain lesions, or moderate to severe 
head trauma were excluded due to potential risks associated with MST and ECT. The presence of 
devices that may be affected by MST or ECT (e.g. pacemakers, cochlear implants, implanted 
brain stimulators, and intracardiac lines) was also a contraindication to treatment. Patients who 
had a history of ECT treatment within the past six months or who had failed to respond to a past 
adequate trial of ECT were excluded as well.  
 
Procedure 
Eligible participants were randomized to receive magnetic seizure therapy (MST) or 
electroconvulsive therapy (ECT) treatment. Of the participants included in later analyses, three 
received MST and three received ECT. They were masked to which treatment they received. 
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Participants assigned to ECT completed a physical exam, blood work, and received medical 
clearance in accordance with the NYSPI Policy and Procedure Manual for ECT.  
 
Psychotropic medication washout: In order to determine the efficacy of MST and ECT in the 
absence of additional treatment, all participants were washed out from psychotropic medications 
for five days prior to treatment with the exception of lorazepam up to 3mg/day. Leading to the 
washout period, each participant received a schedule for tapering medications tailored to their 
regimen and clinical status.  
 
Motor threshold and seizure titration: To determine the intensity of subconvulsive repetitive 
transcranial magnetic stimulation (rTMS) necessary for MST, motor threshold and seizure 
threshold were obtained on the first and last treatment sessions. Motor threshold was defined as 
the minimum magnetic flux necessary to elicit a 50-microvolt peak to peak electromyography 
(EMG) response in five out of ten trials when administering single pulse TMS to the 
contralateral primary motor cortex. Seizure threshold was determined using the stimulus titration 
and ascending method-of-limits procedure, where increasingly powerful stimuli were applied 
until a seizure of adequate duration (≥ 20 seconds) was induced.  
 
Anesthesia: Prior to treatment, all participants were given atropine (0.4 mg i.v.) to prevent post-
seizure bradycardia, general anesthesia, and succinylcholine (0.75-1.0 mg/kg) as an intravenous 
muscle relaxant. Seizure duration was monitored via EEG and motor manifestations. A blood 
pressure cuff was placed and inflated on a limb prior to succinylcholine administration to prevent 
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exposure to the muscle relaxant to that limb, thus allowing observation of the motor seizure 
while reducing risk of injury.  
 
Magnetic seizure and electroconvulsive therapy: MST was administered bilaterally using a 
MagPro coil with simultaneous stimulation over the left dorsolateral prefrontal cortex and to the 
right of vertex at 5x seizure threshold (MagVenture A/S, Farum, Denmark; 50 Hz, biphasic, 370 
µs phase width). Seizure threshold was typically reached at 200 pulses, so that treatment dosage 
was 1000 pulses on post-titration treatment days. ECT was right unilateral at 5x seizure threshold 
(Thymatron ECT Machine, Somatics, LLC, Lake Bluff, IL; Ultrabrief stimulus – 0.25-0.3ms). 
Treatments were administered three times per week, with the number of sessions ranging from 8 
to 18 for participants who completed the study (mean: 14.67, SD: 3.78, Table 1). Treatment was 
terminated at maximal antidepressant effect, when participants reached their lowest score of 
depressive symptoms on the HRSD or showed no further improvement over three subsequent 
treatment sessions. Participants that did not show a clinically significant decline in depressive 
symptoms were offered standard-of-care inpatient clinical treatment at no cost, as determined by 
discussion with their providers.  
 
Measures 
Clinical Ratings 
The primary clinical outcome measure was the 24-item Hamilton Rating Scale for Depression 
(HRSD) (Hamilton, 1960). Typically, scores of 20 or higher on the HRSD are considered 
indicative of moderate to severe depression, while scores in the 0-7 range are considered normal. 
HRSD scores were obtained through clinician rating at baseline prior to treatment and within 
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seven days after the last session. Response to treatment was indicated by a > 50% decrease in 
HRSD score, while remission was indicated by a > 60% decrease or a post-treatment score in the 
normal range. 
 
Neuropsychological Assessment 
Participants completed a neuropsychological battery prior to treatment and within seven days of 
the last session. The battery included measures of verbal ability, visuospatial ability, memory, 
fluency, executive functioning, and motor functioning. The extended 57-point Mini Mental State 
Exam (MMSE) was administered to assess general cognitive impairment (Stern, Sano, Paulson, 
& Mayeux, 1987). The Wide Range Achievement Test (WRAT) was used to assess verbal and 
mathematical ability, specifically the ability to read words, comprehend sentences, spell, and 
perform calculations (Wilkinson & Robertson, 2006). The Rey-Osterrieth Complex Figure Test 
(ROCF) was used to assess visuospatial reasoning, memory, and organization (Rey, 1941). 
Participants were asked to recreate a complex line drawing first by copying it and then by 
memory. The Buschke Selective Reminding Test, Goldberg Remote Memory Test, and 
Autobiographical Memory Index (AMI) were used to assess short-term and long-term memory 
storage and retrieval, as they evaluate recall of spoken words, famous people and events, and 
diverse personal events, respectively  (Buschke, 1973; Goldberg, 1985; Sackeim et al., 1993). 
Digit Span Total, the sum of forward and backward, was used to assess working memory, where 
participants recalled sequences of digits in the order they were presented and in reverse order 
(Wechsler, 2014). The Controlled Oral Word Association Test (COWAT) and the Category 
Fluency Test were used to assess verbal fluency, where participants were asked to name as many 
words starting with a certain letter or belonging within a certain category as possible within a set 
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time period (Ruff, Light, Parker, & Levin, 1996; Lezak, Howieson, & Loring, 1995). The Stroop 
task (word only, color only, and color word conditions) was used to assess processing speed and 
executive functioning (Lezak et al., 1995). Participants read color words, named the color of the 
ink neutral words were printed in, and named the color of the ink of incongruent color words. 
The Trail Making Test was used to assess visuomotor and executive functioning, where 
participants first connected letters in order that were distributed across the page (Trails A: A, B, 
C, etc.). Then, they connected letters and numbers in alternating sets (Trails B: 1, A, 2, B, etc.) 
using a single trace (Lezak et al., 1995). The B/A ratio of scores on the Trail Making Test was 
used to assess executive functioning beyond the effects of visuomotor skill and search speed 
(Martin, Hoffman, & Donders, 2003). The Grooved Pegboard Test was used to assess motor 
dexterity in both the dominant and non-dominant hand, where participants inserted keyed pegs 
into holes with randomly positioned slots (Roy & Square, 1994). The Buschke Selective 
Reminding Test and the ROCF were omitted from analyses due to invalid or missing data.  
 
Electroencephalography: Electroencephalograms (EEG) serve as indirect measures of electrical 
activity from the brain taken at the scalp level. Recordings were obtained at the first session post-
titration (start) and penultimate or last (end) sessions (BrainAmp MR plus amplifiers with 
EasyCap, BrainProducts GmbH, Gilching, Germany). 64-channel EEG was obtained during the 
treatment period, as well as during eyes open and eyes closed resting conditions 15 minutes prior 
to and 15 minutes following treatment (sampling rate: 500Hz, low cutoff: 0Hz, high cutoff: 250 
Hz, online reference electrode: Fpz, ground electrode on left mastoid, no dedicated EOG 
channels).  
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EEG Pre-processing 
64-channel EEG recordings from during treatment sessions were analyzed using BrainVision 
Analyzer 2 (BrainProducts GmbH, Gilching, Germany). Recordings were first visually inspected 
for channels that stopped recording or showed excessive artifacts, which were removed from 
further analysis. Two of eight participants were removed from analysis at this point due to 
recording errors that resulted in the omission of ictal or post-ictal periods. When fewer than six 
channels needed to be removed and they were distributed across the scalp, they were instead 
interpolated as recommended by Picton et al. (2000) using the spherical splines method (Perrin, 
Pernier, Bertrand, & Echallier, 1989). All remaining channels were then average referenced and 
put through a band-pass filter (0.4-100Hz with 12dB/octave rolloff). Eye blinks and movement 
were attenuated using ocular correction independent components analysis. Artifacts were 
automatically marked on individual channels following pre-set criteria: 50 µV/ms maximal 
gradient, 400 µV in 200ms maximal difference, -300 to 300µV amplitude variation, and 0.5µV 
for 100ms minimal activity. The gradient criterion marked large differences between consecutive 
sampling points, the difference criterion marked large differences between minimum and 
maximum within a sliding window segment, the amplitude criterion marked extreme amplitude 
values, and minimal activity marked very low differences between minimum and maximum 
values within a segment. In combination, these artifact detection criteria ensured that non-
recording electrodes and noise from movement, muscle contractions, or electrical interference 
did not affect further analyses.  
 
Ictal and post-ictal start and end markers were placed according to visual inspection. The ictal 
period was defined as the period immediately following ECT or MST stimulation until the end of 
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seizure activity as observed in the EEG. Motor observations of seizure duration were used to 
guide marker placement. Two post-ictal periods were defined as the two subsequent 10-second 
periods following the ictal period.  
 
EEG Analysis 
The first 10 seconds of the ictal period were extracted for equivalent duration to the post-ictal 
periods. 10 frontal channels were analyzed, five on the left (AF3, F1, F3, F5, FC3) and five on 
the right (AF4, F2, F4, F6, FC4) (Figure 1). Previously marked artifacts in the frontal channels 
were removed by setting waveform values during the artifact to the value immediately preceding 
the artifact in order to produce a flat line with zero slope. All values following the artifact were 
then shifted to connect to the new value at the end of the artifact. Though this method is not 
commonly used in EEG analysis, it avoids false artifacts that would arise from cutting out 
artifacts and splicing together the remaining data, as well as a false low-frequency signal that 
would arise from connecting the remaining data with a sloped line.  
 
Ictal and post-ictal periods underwent a 60 Hz notch filter, then a Morlet wavelet transform in a 
custom MATLAB script (Lakatos, Chen, O’Connell, Mills, & Schroeder, 2007) to determine 
average power within each of five frequency bands (delta: 0.5-4 Hz, theta: 4-8 Hz, alpha: 8-12 
Hz, beta: 14-28 Hz, gamma: 30-58 Hz). Power values of zero obtained from artifact removal 
were excluded from the averaging, as well as power values greater than two standard deviations 
away from the mean for each frequency band. The Morlet wavelet function is a transformation 
that decomposes the EEG signal into its constituent frequency components while maintaining the 
time domain, unlike fast Fourier transforms (Grossmann & Morlet, 1984). These frequency 
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components can then be grouped into bands and their power analyzed at different time points or 
averaged across a specified period for each channel. This analysis resulted in average power 
values for five frequency bands for each of ten frontal channels within three periods (ictal, post-
ictal 1, and post-ictal 2). These average power values were calculated for each participant at their 
start and end treatment sessions.   
 
Power was averaged across channels within each hemisphere, then the hemispheres were 
averaged to obtain power values representative of frontal EEG. Post-ictal suppression was 
calculated as the difference in power between the ictal period and the first post-ictal period. To 
assess change in EEG across the course of treatment, differences in ictal power and post-ictal 
suppression between the start session and the end session were calculated.  
 
Statistical Analysis 
A repeated-measures ANOVA was used to assess the main effects and interactions of treatment, 
session, period, and hemisphere on power (afex, R package version 0.16-1, 2016). Hemisphere 
(left or right), session (start or end), and period (ictal, post-ictal 1, or post-ictal 2) were within-
subjects factors while treatment (MST or ECT) was the between-subjects factor. Post-hoc 
analyses assessed the direction of main effects and interactions between factors (lsmeans, R 
package version 2.26-3, 2016).  
Since treatment termination was determined by decrease in HRSD score, treatment duration 
varied by participant. Pearson’s correlation analyses assessed the relationship between the 
number of treatments and changes in ictal power and post-ictal suppression for the five 
frequency bands.   
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To examine the relationship between EEG characteristics and performance on 
neuropsychological tests, hierarchical/sequential multiple regression analyses were used. Test 
performance was first regressed only on treatment (Model 1), then on treatment and change in 
ictal power (Model 2a), or treatment and change in post-ictal suppression (Model 2b). ΔR2 from 
Model 1 to Model 2 indicated the increased fit of the regression model when considering change 
in ictal power or post-ictal suppression after controlling for treatment. Model 2 analyses with 
ΔR2 > .7 were investigated further. Finally, the interaction between treatment and change in ictal 
power (Model 3a) or change in post-ictal suppression (Model 3b) was added to each 
respectively.  
Results 
Five (2 ECT, 3 MST) of six patients responded to treatment and achieved remission of 
depression symptoms as indicated by >60% decrease in HRSD score (Table 1). MST responders 
showed a range of 13 to 18 treatment sessions, while ECT responders showed a range of 16 to 18 
sessions. Neither treatment nor the number of treatment sessions predicted change in ictal power 
or change in post-ictal suppression for any of the frequency bands.  
Power did not differ between left and right hemispheres and hemisphere did not interact with 
other factors, so power was averaged across hemispheres for the following analyses. The effects 
of treatment, session, and period on average frontal power within the five frequency bands for 
the five responders were assessed using a repeated-measures ANOVA (Table 2). Power did not 
differ by treatment for any of the frequency bands. Power differed by session for theta and alpha, 
where the end session showed higher power on average than the start session. Though power did 
not significantly differ by period, power during the ictal period tended to be higher than during 
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either of the post-ictal periods (Figure 2). There was a significant interaction between session 
and period for delta, theta, and alpha bands. Post-hoc analyses indicated that the ictal power was 
higher during the end session than the start session, while post-ictal power did not differ across 
sessions (Figure 2). By contrast, the non-responder did not show as marked post-ictal 
suppression or an increase in ictal power for the end session.   
Neuropsychological assessment 
Model 1 of hierarchical regression analyses regressed change in test performance from start to 
end session on treatment. Treatment did not significantly predict change in test performance for 
any tests. Models 2a and 2b predicted test performance from treatment and change in ictal power 
or change in post-ictal suppression, respectively. Neither change in ictal power nor post-ictal 
suppression predicted change in performance on the Goldberg Remote Memory Test, the 
Category Fluency Test, Digit Span, the Autobiographical Memory Index, or the Stroop task, 
after controlling for treatment  
However, change in ictal power or post-ictal suppression did contribute to change in Trails, 
COWAT, and Grooved Pegboard performance. An increase in gamma ictal power or post-ictal 
suppression significantly predicted an increase in Trails B/A ratio after controlling for treatment 
(Table 3, Model 2; Figure 3). Since the Trails B/A ratio represents executive functioning in 
switching sets, an increase in the ratio indicates slowing of cognitive functioning. Thus, larger 
increases in gamma ictal power and gamma post-ictal suppression across the course of treatment 
were associated with greater impairment of executive functioning.  
An increase in beta ictal power or post-ictal suppression also significantly predicted an increase 
in COWAT score after controlling for treatment (Table 4, Model 2; Figure 4). An increase in 
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theta post-ictal suppression significantly predicted an increase in COWAT score after controlling 
for treatment, and there was a trend towards an association between an increase in theta ictal 
power and COWAT score (Table 5, Model 2; Figure 5). An increase in COWAT score indicates 
improved performance, so increased theta and beta ictal power and theta post-ictal suppression 
were associated with improvements in verbal fluency.   
An increase in alpha ictal power may be associated with an increase in Grooved Pegboard Non-
dominant score (Table 6, Model 2a; Figure 6), where an increase in score indicates slowing in 
motor performance. The interaction between treatment and change in ictal power or post-ictal 
suppression did not contribute to any of the models generated. Therefore, treatment did not 
moderate the effect of ictal power or post-ictal suppression on cognitive performance.  
Discussion 
This study presents the first human neurophysiological findings using high-density EEG 
comparing ECT and MST for the treatment of severe depression. The primary finding of this 
study involved the differential pattern of ictal expression across the course of treatment between 
the responders and the non-responder. All patients showed increased power during the ictal 
period than the post-ictal periods, though the small sample size limited statistical significance. 
However, ictal power and post-ictal suppression were markedly larger for the responders in all 
frequency bands. An interaction between session and period in the responder group indicated a 
change in the seizure characteristics across the course of treatment, where seizures at the end of 
treatment showed greater power and larger post-ictal suppression than at the beginning of 
treatment. This change across treatment was not seen in the non-responder, which suggests that 
an increase in ictal power and a corresponding increase in post-ictal suppression may be linked 
to therapeutic response. Such a link between global ictal power and post-ictal suppression, 
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particularly in the delta band, with therapeutic response has been found in the ECT literature, but 
has not yet been generalized to MST or other frequency bands (Engel et al., 2016; Mayur, 2006). 
By using an active cap to record quality signal in frequencies up to 60Hz, this study found 
patterns of increasing ictal power and post-ictal suppression in higher frequencies as well as in 
MST.  
Of the six patients with complete data, all of the three MST patients obtained remission of 
depression symptoms within 18 sessions, which was a treatment duration similar to that of ECT 
response in this study. However, a study of ECT in the elderly reported a mean of 7.3 sessions to 
reach remission and typical ECT treatment courses are only 8-12 sessions (Blumberger et al., 
2015; Engel et al., 2016). The longer treatment duration of this study was likely due to the 
termination criteria of maximal antidepressant effect such that patients could have met criteria 
for remission, then continued to show reduction in depression symptoms for several sessions 
before treatment termination. Nevertheless, these results support the antidepressant efficacy of 
MST in comparison to ECT in a randomized trial. 
In contrast to past research, MST and ECT did not differ in terms of power in either the ictal or 
post-ictal periods. Non-human primate and human studies have found that MST results in lower 
ictal power and less post-ictal suppression than ECT (Cycowicz et al., 2009; Lisanby et al., 
2003). However, recent development of the MST equipment has allowed for greater output 
intensity such that the energy multiplier of the seizure threshold used in MST stimulation more 
closely resembles that of ECT. Therefore, differences in ictal power in past literature may have 
reflected limitations of MST technology at the time. MST and ECT also did not differ in terms of 
their effects on cognitive functioning. 
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Change in ictal power and post-ictal suppression across the course of treatment were linked to 
changes in cognitive functioning, though the relationships differed between domains of 
functioning. Increases in ictal power and post-ictal suppression were linked to slowing on Trails 
and Grooved Pegboard, but an improvement in the COWAT. An improvement in 
neuropsychological functioning post-treatment was found in another randomized trial of MST vs. 
ECT with medium effect sizes for measures of visuospatial learning, but there was a slight 
decline in performance for verbal fluency (Kayser et al., 2015). The improvements in cognitive 
functioning may have been due to a reversal of baseline cognitive deficits associated with severe 
depression. The differences in performance found in this study do not closely replicate those 
found by Kayser et al. (2015), but they may be explained in terms of the particular domains of 
functioning adversely affected by treatment. Though the second portion of the Trail-Making Test 
assesses the ability to alternate sets and monitor performance, it also relies heavily on visual 
search and visuomotor skills. The ratio score for Trails is meant to account for the effect of 
motor functioning as it considers performance on a simpler visual search task, but it does not 
account for the increased demand on visuomotor skills given the larger number of potential 
targets to search through and connect. Performance on the Grooved Pegboard test also relies 
heavily on visuomotor skills. As the COWAT is administered orally, it does not require any 
visual or motor responses. The difference in association between ictal power or post-ictal 
suppression and cognitive functioning may reflect treatment’s specific effects on visuomotor 
functioning while verbal fluency and other aspects of executive functioning are preserved or 
improved.  
Though this study presents new findings regarding potential neurophysiological characteristics of 
therapeutic response to MST, these results are subject to limitations. Sample size was a major 
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limitation to interpreting results involving differences between treatments. Based on estimated 
small effect sizes between MST and ECT, power analyses indicated that a sample size of seven 
per group would be necessary to better assess the effects of treatment and period on power 
(G*Power, Version 3.1, 2014). Lack of an MST non-responder was another limitation, as a non-
responder for comparison to the responder group would provide further evidence to whether the 
relationship between therapeutic response and ictal power and post-ictal suppression applies to 
MST as well as ECT.  
Additional studies should continue to examine neurophysiological characteristics associated with 
therapeutic response in MST, and to what extent these relationships match those found in ECT. 
Specifically, though this study suggests a general association between higher ictal power and 
post-ictal suppression with treatment response, evidence for that link in MST is scarce. It is also 
unclear whether the same degree of ictal power and post-ictal suppression as seen in ECT is 
necessary for equivalent treatment outcomes. Understanding the neurophysiological 
characteristics of seizures linked to treatment response would aid the optimization of ECT and 
MST parameters for efficacy.  
To present a comprehensive picture of MST as an alternative treatment to ECT for depression, 
side effect profiles, particularly cognitive and motor side effects, should be investigated further. 
Examining EEG in other areas (e.g. temporal lobe, occipital lobe) may elucidate connections 
between seizure expression and the visuomotor side effects found in this study. Beyond the 
baseline and post-treatment markers obtained in this study, check-ins during treatment and three 
and six months following treatment termination would provide information regarding the time 
course of side effects. The feasibility of MST depends on whether it presents fewer, less 
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impairing, and less chronic side effects. Thus, neuropsychological outcomes should be assessed 
at regular intervals during and after treatment.  
Overall, this study demonstrated the efficacy of MST in geriatric patients with severe depression, 
and identified patterns of ictal expression that may be indicative of therapeutic response. These 
results further support the feasibility and efficacy of MST as an alternative treatment to ECT.  
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Figures 
Figure 1. Topographic map of ten frontal channels (circled) extracted 
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Figure 2. Power during ictal and post-ictal periods for start and end sessions. Error bars indicate 
standard error of the mean.  
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Figure 3. Relationship between change in Trails B/A ratio score and (a) change in ictal power or 
(b) change in post-ictal suppression in the gamma band.  
 
 
 
 
 
 
 
 
 
 
Figure 4. Relationship between change in COWAT score and (a) change in ictal power or (b) 
change in post-ictal suppression in the beta band.  
 
  
a b 
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Figure 5. Relationship between change in COWAT score and (a) change in ictal power or (b) 
change in post-ictal suppression in the theta band. 
 
 
Figure 6. Relationship between change in Grooved Pegboard score and change in ictal power in 
the alpha band. 
 
  
a b 
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Tables 
Table 1. Patient characteristics and treatment response 
 
 
Table 2. Repeated-measures ANOVA to assess effects of treatment, session, period, and their 
interactions on average frontal power for five frequency bands (Greenhouse-Geisser corrected) 
 Delta Theta Alpha Beta Gamma 
 F p F p F p F p F p 
Treatment 0.06 0.82 0.44 0.56 0.26 0.65 0.39 0.58 0.71 0.46 
Session 2.82 0.19 33.81 0.01* 12.59 0.04* 8.16 0.06+ 8.47 0.06+ 
Period 3.92 0.14 2.35 0.22 4.97 0.11 5.55 0.10+ 6.30 0.08 
Treatment x 
Session 
0.60 0.49 0.02 0.89 0.31 0.62 0.04 0.85 0.01 0.92 
Treatment x 
Period 
0.28 0.64 0.27 0.64 0.17 0.71 0.33 0.61 0.53 0.52 
Session x 
Period 
13.06 0.03* 14.12 0.03* 12.58 0.02* 4.64 0.12 8.23 0.05+ 
Treatment x 
Session x 
Period 
5.60 0.10+ 1.66 0.29 0.12 0.82 0.27 0.65 0.81 0.44 
* p < 0.05, + p ≤ 0.10 
 
 
ID Sex Age Treatment # Sessions Pre HRSD Post 
HRSD 
Status 
4011 M 74 ECT 18 27 6 Responder 
4012 F 62 MST 15 25 2 Responder 
4013 F 74 MST 18 38 8 Responder 
4016 F 63 MST 13 34 7 Responder 
4017 F 57 ECT 16 26 7 Responder 
4018 F 59 ECT 8 22 20 Non-responder 
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Table 3. Summary of hierarchical regression analysis for treatment and change in EEG (gamma) predicting change in Trails B/A ratio 
(N=6) 
 Model 1 Model 2a Model 3a Model 2b Model 3b 
Variable B SE B β B SE B β B SE B β B SE B β B SE B β 
Treatment -.12 .57 -.10 .05 .15 .04 .09 .36 .08 -.01 .15 -.01 .07 .37 .06 
Change in EEG    .03 .003 .98** .03 .004 .97* .03 .003 .97** .03 .004 .96* 
Treatment x EEG       .002 .01 .05    .004 .02 .08 
Adjusted R2 -.24 .92 .88 .92 .88 
F for ΔR2 .04 58.50** .02 57.99** .05 
+ p < .10, * p < .05, ** p < .01 
Table 4. Summary of hierarchical regression analysis for treatment and change in EEG (beta) predicting change in COWAT score 
(N=6) 
 Model 1 Model 2a Model 3a Model 2b Model 3b 
Variable B SE B β B SE B β B SE B β B SE B β B SE B β 
Treatment -6.00 8.62 -.33 -5.10 4.72 -.28 -5.15 8.11 -.28 -4.93 4.32 -.27 -5.94 6.89 -.33 
Change in EEG    .15 .05 .83* .15 .08 .84 .14 .04 .85* .15 .07 .92 
Treatment x EEG       -.001 .11 -.005    -.02 .09 -.11 
Adjusted R2 -.11 .67 .50 .72 .59 
F for ΔR2 .49 10.39* <.001 13.01* .05 
+ p < .10, * p < .05, ** p < .01 
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Table 5. Summary of hierarchical regression analysis for treatment and change in EEG (theta) predicting change in COWAT score 
(N=6) 
 Model 1 Model 2a Model 3a Model 2b Model 3b 
Variable B SE B β B SE B β B SE B β B SE B β B SE B β 
Treatment -6.00 8.62 -.33 -8.12 5.59 -.45 3.38 16.83 .19 -7.24 4.24 -.40 -6.85 8.26 -.38 
Change in EEG    .16 .06 .79+ .14 .07 .70 .11 .03 .86* .11 .05 .84 
Treatment x EEG       .14 .19 .67    .004 .07 .03 
Adjusted R2 -.11 .54 .46 .73 .60 
F for ΔR2 .49 6.73+ .54 13.65* .004 
+ p < .10, * p < .05, ** p < .01 
Table 6. Summary of hierarchical regression analysis for treatment and change in EEG (alpha) predicting change in Grooved 
Pegboard Non-dominant score (N=6) 
 Model 1 Model 2a Model 3a Model 2b 
Variable B SE B β B SE B β B SE B β B SE B β 
Treatment -5.03 15.40 -.16 7.41 10.17 .24 31.37 10.54 1.00+ 5.04 14.10 .16 
Change in EEG    .27 .09 .93+ .12 .08 .41 .17 .10 .76 
Treatment x EEG       .29 .11 1.19    
Adjusted R2 -.22 .57 .86 .16 
F for ΔR2 .11 8.21+ 7.37 2.82 
+ p < .10, * p < .05, ** p < .01 
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